Please assess the completion status of the following clinical trial:

Trial Title: Palliative Management of Inoperable Malignant Bowel Obstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years of age.~* Diagnosis of partial bowel obstruction secondary to active or prior malignancy (primary or metastatic GI, GYN, and carcinomatosis) caused either by tumor itself or adhesions inthe setting of active malignancy.~* Cross-sectional imaging performed within 24 hours of clinical symptoms of bowel obstruction (nausea, vomiting, and constipation ± abdominal pain) during hospital admission.~* Patient must have an inoperable MBO~* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved writteninformed consent form prior to receiving any study related procedure.~Exclusion Criteria:~* Evidence of complete bowel obstruction by imaging.~* Bacteremia/septicemia with a documented positive blood culture: If a blood culture comes back positive after study enrollment, patient will be excluded.~* Patients already taking a steroid equivalent to 8 mg of dexamethasone per day prior to study enrollment.~* Patients undergoing bowel surgery or stent placement for bowel obstruction.~* Those patients with MBO in setting of incarcerated hernia.~* Known history of QT prolongation syndrome or if QTc is \> 450 msec in males or \> 470 msec in females on baseline EKG within 2 weeks of enrollment.~* Lack of decision making capacity/delirium.~* Pregnant or nursing female participants.~* Actively suicidal patients.~* Acute cholecystitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (octreotide, dexamethasone, metoclopramide) (Type: EXPERIMENTAL): IV octreotide 300 mcg TID + IV dexamethasone 4 mg BID (first dose 9am and second at 2pm) + IV metoclopramide 10 mg q6h.

Based on this trial design, predict the completion outcome and termination type (if applicable).